Explore how generic drug exclusivity periods vary across the US, EU, and other regions. Learn why generics are delayed despite patent expirations and how new regulations impact drug prices.
Discover how generic drugs and biosimilars saved the US healthcare system $3.4 trillion over a decade and why they are critical for keeping prescription costs manageable.
Patent litigation in the generic drug market is delaying affordable medicines by years. Learn how the Hatch-Waxman Act, Orange Book abuses, and serial lawsuits are blocking competition-and what’s being done to fix it.